We are live on ! Find out more
VBIV

VBI Vaccines, Inc. New Common Stock (Canada)
VBIV

Delisted

VBIV was delisted on the 7th of August, 2024.

Back to rankings

10 hedge funds and large institutions have $18.1M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,190% more capital invested

Capital invested by funds: $422K → $18.1M (+$17.7M)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

67% more funds holding

Funds holding: 6 → 10 (+4)

Holders
10
Holders Change
+4
Holders Change %
+66.67%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CV
Clarus Ventures
Massachusetts
+$18.3M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$3.44M
3
U
UBS
Switzerland
+$12.6K
4
Bank of America
Bank of America
North Carolina
+$5.64K
5
Morgan Stanley
Morgan Stanley
New York
+$3.76K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$10K

VBIV Hedge Fund Activity: Q3 2014 in Review

10 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2014, worth a combined $18.1M — up 4,190% from $422K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VBIV positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Clarus Ventures, opening a new position worth an estimated $18.3M. The largest seller was Citadel Advisors, exiting entirely with an estimated $10K sold.

  • 10 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2014, up from 6 in Q2 2014.
  • Funds reported $18.1M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2014, up 4,190% quarter-over-quarter.
  • 5 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2014 and 1 closed out, a net change of +4 holders.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q3 2014 was Clarus Ventures, an estimated $18.3M added.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2014 was Citadel Advisors, an estimated $10K sold.

Based on aggregated 13F filings for Q3 2014.